Reports of Respiratory Syncytial Virus (RSV) vaccine administration errors in pregnant women

June 24, 2026

The Department of Health has been notified of reports of Respiratory Syncytial Virus (RSV) vaccine administration errors, where Arexvy® has been administered to pregnant women instead of Abrysvo®.


These reports align with the expanded use of RSV vaccines in older adults under the National Immunisation Program.

What you need to know:

  • Abrysvo® is the ONLY RSV vaccine recommended for use in pregnancy under the NIP.
  • Arexvy® is registered for use in older adults and should NOT be administered to pregnant women.

Providers are asked to take the following steps to prevent administrative errors:

Before vaccination

  • Confirm the correct RSV vaccine under the National Immunisation Program
  • Confirm patient eligibility, including pregnancy status
  • Check the vaccine brand carefully prior to preparation and administration
  • Follow the “6 rights” of medication administration (right person, vaccine, dose, time, route, documentation) to prevent vaccine administration error

Storage and handling

  • Clearly separate and label RSV vaccines in the vaccine refrigerator
  •  Avoid storing Arexvy® alongside vaccines used in antenatal programs where possible

After vaccination

  • Report all vaccine administration errors and adverse events to SAEFVIC as soon as possible
  • Ensure appropriate clinical follow-up and open disclosure where an error has occurred
  • Record all vaccine encounters in the Australian Immunisation Register (AIR)

Further guidance on vaccine error management is available on the Department of Health website.

Latest news

October 1, 2026
From 1 October 2026, COVID-19 vaccines will be funded under the National Immunisation Program (NIP), replacing the National COVID-19 Vaccine Program (NCVP) that was established during Australia’s response to the COVID-19 pandemic.
September 30, 2026
SEMPHN's 2026 Stakeholder Survey has found stakeholder experience improved across almost every measure, with stakeholders continuing to identify responsive staff, practical support and collaborative relationships as key strengths.
September 30, 2026
The Australian Government Department of Health, Disability and Ageing has opened two competitive national grant opportunities aimed at reducing the harms associated with Alcohol and Other Drugs (AOD) use and improving treatment access and outcomes.